DOCSLIB.ORG

Hematologie 2021 POST-ASH

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hematologie 2021 POST-ASH ONLINE 21. PRAŽSKÉ HEMATOLOGICKÉ DNY Hematologie 2021 POST-ASH KAM NÁS POSOUVÁ TO NEJLEPŠÍ Z LOŇSKÉ SVĚTOVÉ HEMATOLOGIE 28. – 29. 1. 2021 Clarion Congress Hotel Prague (Freyova 33, Praha 9 – Vysočany) PROGRAM KONFERENCE A SBORNÍK ABSTRAKTŮ 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 OBSAH 2 POST-ASH OBSAH 2 ÚVODNÍ SLOVO 3 DŮLEŽITÉ INFORMACE 4 SCHÉMA ODBORNÉHO PROGRAMU 6 PODROBNÝ PROGRAM KONFERENCE 7 POSTEROVÁ SEKCE 11 OŠETŘOVATELSKÝ PROGRAM 16 SATELITNÍ SYMPOZIA 18 SBORNÍK ABSTRAKTŮ 25 ABECEDNÍ REJSTŘÍK AUTORŮ 119 PŘEHLED PARTNERŮ A VYSTAVOVATELŮ 122 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 ÚVODNÍ SLOVO 3 POST-ASH Vážené kolegyně, vážení kolegové, milí hosté 21 pražských hematologických dnů-HEMATOLOGIE 2021, loni jsme na 20 pražských hematologických dnech zahájili novou tradici, kterou účastníci velmi přivítali: uspořádat konferenci na začátku roku a reflektovat při nich to nejlepší, co se v našem oboru odehrálo na loňských světových kongresech Jsou to především ASH a EHA, ale i více specializované konference I když celý loňský rok poznamenala pandemie, bylo nám celou dobu jasné, že úspěšnou tradici nesmíme přerušit Optimisté v našich řadách doufali, že se podaří uspořádat konferenci v klasickém formátu, nicméně připravovali jsme paralelně všechny varianty Nakonec zvítězila varianta výhradně online Podobně jako našim dětem chybí interakce se spolužáky, i my budeme postrádat milá setkání s kolegy, hovory ve frontě na kávu, diskusi v přednáškových sálech i chutný štrůdl v hotelu Clarion Na co se ale těšit můžete: z pohodlí domova, kanceláře či lékařského pokoje se můžete připojit, nemusíte platit registrační poplatky a uslyšíte kvalitní edukační i původní přednášky Postery si můžete prohlédnout, kdy se Vám to bude hodit a navíc můžete využít posterovou sekci Při ní uvidíte kratičké prezentace autorů, my coby moderátoři se budeme snažit rozproudit diskusi a upozornit všechny na výsledky, které nás zaujaly Pro všechny přednášky a sdělení platí, že je budeme vysílat buď ze studia z Clarionu nebo z prostředí, které si zvolí přednášející Rozhodli jsme se část odborného programu věnovat tomu, co nás od roku 2020 obklopuje Sdělení na covidová témata nemají za cíl opakovat zpravodajství hlavních serverů a způsobit mezi účastníky vegetativní reakci, ale prezentovat ověřené poznatky z oblasti imunologie infekce a v ošetřovatelském bloku předat praktické informace, které Vám pomohou při každodenní práci nejen s pacienty s COVIDem Očekáváme vysoký počet účastníků, takže autoři přednášek se mohou těšit na široké obecenstvo a odpovídající diskusi Děkujeme firmám za účast a podporu a těšíme se, že připraví kvalitní sympozia Milí kolegové, těšíme se na setkání s Vámi, byť virtuální a doufáme, že Vás 21 pražské hematologické dny - HEMATOLOGIE 2021 zaujmou Ondřej Hrušák Marek Trněný předseda organizačního a vědeckého výboru prezident 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 DŮLEŽITÉ INFORMACE 4 POST-ASH TERMÍN KONÁNÍ ONLINE KONFERENCE 28. – 29. 1. 2021 Online verzi, prosíme, sledujte ve dnech 28. – 29. 1. 2021 na: www.phd.cz ve dnech a časech: čtvrtek 28 1 2021 11 00 – 19 00 hodin pátek 29 1 2021 11 15 – 15 45 hodin Záznam všech přednášek z konference bude dostupný pro všechny registrované účastníky na webu akce od 10. 2. 2021 až po dobu 3 měsíců. REGISTRACE Online sledování je pro všechny účastníky ZDARMA, po provedené registraci. Registrační formulář je k dispozici online na webových stránkách konference Po odeslání registračního formuláře se objeví potvrzení, že registrace byla v pořádku odeslána a po několika minutách obdržíte potvrzení o Vaší registraci Jako vstupní přihlašovací kód do online vysílání, prosíme, zadejte e-mailovou adresu zadanou při registraci V případě problémů s přihlášením nás neváhejte kontaktovat na bilkova@meritis cz nebo tel čísle: +420 739 571 536 CERTIFIKÁTY Akreditovaná akce systému celoživotního vzdělávání je garantována ČLK a ohodnocena kreditními body Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č 16 Konference je určena pro odbornou veřejnost Certifikáty budou zaslány elektronicky 14 dní po skončení konference všem registrovaným účastníkům, kteří sledovali ONLINE přenos. 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 POŘADATEL 5 POST-ASH SPOLEK ČESKÝCH LÉKAŘŮ V PRAZE ČLS JEP Prezident konference: Garanti ošetřovatelského programu: pod záštitou: Marek Trněný Darja Hrabánková České hematologické společnosti ČLS JEP Lucie Vylitová Emeritní prezident: Lenka Turková České společnosti pro trombózu Pavel Klener Jitka Wintnerová a hemostázu ČLS JEP Předseda organizačního Garanti paliativního bloku: ve spolupráci s: a vědeckého výboru: Klinika paliativní medicíny VFN a 1 LF UK Ondřej Hrušák Tým dětské podpůrné a paliativní péče FN Motol I. interní klinikou - klinikou hematologie Tým podpůrné a paliativní péče ÚHKT VFN a 1. lékařské fakulty UK v Praze Organizační a vědecký výbor, Kateřina Rusinová členové: Lucie Hrdličková Ústavem hematologie a krevní transfuze Petr Cetkovský Michal Kouba Jaroslav Čermák Klinikou dětské hematologie a onkologie Jan Evangelista Dyr † FN Motol a 2. lékařské fakulty UK v Praze Anna Jonášová Pavel Klener jr Hematologickou klinikou FN Královské Tomáš Kozák Vinohrady a 3. lékařské fakulty UK v Praze Peter Salaj Jan Starý Tomáš Stopka Jan Trka 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 SCHÉMA ODBORNÉHO PROGRAMU 6 POST-ASH čtvrtek 28. 1. 2021 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 SEKCE 1 11:00 Zahájení konference SEKCE 2 pátek 29. 1. 2021 SEKCE 1 15:45 Zakončení Legenda: konference EDUKAČNÍ PROGRAM PŘEDNÁŠKOVÁ SDĚLENÍ SEKCE 2 SATELITNÍ SYMPOZIA OŠETŘOVATELSKÝ PROGRAM POSTEROVÁ SEKCE 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 PODROBNÝ PROGRAM KONFERENCE 7 POST-ASH čtvrtek 28. 1. 2021 čas SEKCE 1 čačas s SEKCE 2 11:15 - 12:00 Satelitní sympozia (více na straně 19) 11:15 - 12:00 Satelitní sympozia (více na straně 19) 12:00 - 13:00 Satelitní sympozia (více na straně 20) 12:00 - 13:00 Satelitní sympozia (více na straně 20) 13:00 – 14:30 Odborný program - Blok I 13:00 – 14:30 Odborný program - Blok IV Předsedající: Zuna J. (Praha) Předsedající: Cetkovský P. (Praha) 13:00 - 13:20 E01 Ph-negativní chronická myeloproliferativní onemocnění 13:00 - 13:20 E07 Myelom - přehled z ASH 2020 a chronická myeloidní leukemie na ASH 2020 Špička I. (Praha) Faber E. (Olomouc) 13:20 - 13:35 O03 Identification of novel regulatory pathway for 13:20 - 13:35 O01 Major molecular response is the threshold for NGS immunoglobulin production provides rational treatment analysis and resistant BCR-ABL1 mutation detection in CML for bortezomib-resistant multiple myeloma patients Machová Poláková K (Praha) a spol. - OCENĚNÁ SDĚLENÍ MLADÝCH HEMATOLOGŮ Šimíček M. (Ostrava) a spol. 13:35 - 13:55 E02 Anémie ve stáří a klonální hematopoéza Čermák J. (Praha) 13:35 - 13:50 O04 miR-29 Influences CD40 Signaling in Chronic Lymphocytic Leukemia (CLL): An Axis Affected by BCR Inhibitors 13:55 - 14:10 O02 Diagnostic yield of bronchoalveolar lavage (BAL) in Mráz M. (Brno) a spol. haematological patients - single centre 14 years experience Palacková M. (Brno) a spol. 13:50 - 14:05 O05 Single-Cell Profiling of Signal Transduction Pathways in pediatric T-Cell Acute Lymphoblastic 14:10 - 14:30 E03 Trombóza a hemostáza ve světle aktuálních poznatků Leukemia by Mass Cytometry: Dissecting JAK/STAT Penka M. (Brno) and PI3K/AkT/mTOR Active Signalling - OCENĚNÁ SDĚLENÍ MLADÝCH HEMATOLOGŮ Kužílková D. (Praha) a spol. 14:05 - 14:25 E08 CAR buněčná terapie v léčbě lymfoidních malignit Pytlík R. (Praha) 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 PODROBNÝ PROGRAM KONFERENCE 8 POST-ASH čtvrtek 28. 1. 2021 čas SEKCE 1 s SEKCE 2 14:30 – 15:55 SLAVNOSTNÍ ZAHÁJENÍ KONFERENCE 14:30 - 14:45 Zahájení konference 14:45 - 15:15 Neuwirtova přednáška: Problematika poruch hemokoagulace v České republice Dyr J E (Praha) Kotlín R , Štikarová J (Praha) 15:15 - 15:45 Heřmanského přednáška: Pokrok v léčbě leukémie u dětí v novém tisíciletí Starý J (Praha) 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 PODROBNÝ PROGRAM KONFERENCE 9 POST-ASH čtvrtek 28. 1. 2021 čas SEKCE 1 16:00 – 17:30 Odborný program - Blok II Předsedající: Trka J. (Praha) 16:00 - 16:15 Integration of COO into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL - oceněná práce ČHS Klánová Zikmundová M. (Praha) SAVE THE DATE! 16:15 - 16:30 Genomic landscape of pediatric B-other acute lymphoblastic leukemia SRDEČNĚ VÁS ZVEME NA - oceněná práce ČHS 22. PRAŽSKÉ HEMATOLOGICKÉ DNY Žaliová M.(Praha) HEMATOLOGIE 2022 - POST-ASH 16:30 - 16:50 E04 Imunologie COVID-19 a péče o hematoonkologické pacienty 20. - 21. 1. 2022 Hrušák O. (Praha) 16:50 - 17:10 E05 Paliativní medicína na ASH: 62th Annual Meeting Rusinová K. (Praha) 17:10 - 17:30 E06 Pediatrie na ASH 2020 Pospíšilová D. (Olomouc) 17:35 – 19:00 Posterová sekce Moderují: Hrušák O. (Praha), Trka J. (Praha) 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 PODROBNÝ PROGRAM KONFERENCE 10 POST-ASH pátek 29. 1. 2021 čas SEKCE 1 čas SEKCE 2 11:15 - 12:00 Satelitní sympozia (více na straně 21) 11:15 - 12:00 Satelitní sympozia (více na straně 21) 12:00 - 12:45 Satelitní sympozia (více na straně 22) 12:00 - 12:45 Satelitní sympozia (více na straně 22) 12:45 - 13:30 Satelitní sympozia (více na straně 23) 12:45 - 13:30 Satelitní sympozia (více na straně 23) 13:30 - 15:00 Odborný program - Blok III 13:30 - 15:00 Odborný program - Blok V Předsedající: Trněný M. (Praha) Předsedající: Kozák T. (Praha) 13:30 - 13:50 E09 Non-Hodgkinovy lymfomy 13:30 - 13:50 E12 Transplantace kmenových buněk krvetvorby u dětí s akutní Janíková A. (Brno) lymfatickou leukémií, po 50 letech už víme kdy a jak? Sedláček P. (Praha) 13:50 - 14:05 O06 Targeting anti-apoptotic MCL1 protein with S63845 is highly effective in aggressive B-cell Non-Hodgkin 13:50 - 14:05 O08 In vitro and in vivo preclinical models for testing lymphomas with non-expression of BCL2 new therapies for AZACITIDINE-RESISTANT MDS/AML Klánová M.
Load more

Recommended publications
  • Study Protocol: Amendment 3
    (!') GILEAU CLINICAL STUDY PROTOCOL Study Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Unu·eated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-fmding, Lead-in Phase Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA IND Number: 120605 EudraCT Number: 2014-004480-20 ClinicalTrials.gov Identifier: NCT021 01021 Indication: Previously unu·eated metastatic pancreatic ductal adenocarcinoma Protocol ID: GS-US-370-1296 Clinical Trials Manager: Name: PPD Telephone: PPD Gilead Medical Monitor: Name: Peter Lee, MD, PhD Telephone: PPD Clinical Program Manager: Name: PPD Telephone: PPD Protocol Version/Date: Original: 11 Febmary 2014 Amendment 1: 14 March 2014 Amendment 2: 25 August 2014 Amendment 3: 16 July 2015 CONFIDENTIALITY STATEMENT The inf01mation contained in this document, pruiicularly unpublished data, is the prope1iy or under conu·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The infonnation is only to be used by you in connection with authorized clinical studies of the investigational dmg described in the protocol. You will not disclose any of the infonnation to others without written authorization from Gilead Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those persons
    [Show full text]
  • Abstract Supplement
    2018 ABSTRACT SUPPLEMENT SAN FRANCISCO June 20-23 • Marriott Marquis Federation of Clinical Immunology Societies June 20-23, 2018 San Francisco, California FOCIS 2018 Abstract Supplement TABLE OF CONTENTS Abstracts by Subject Area …………………………………………………………...……………………………….2 Allergy/asthma ……………………………………………………………………………………………………...2 Autoimmune neurologic diseases .............................................................................................................. 7 Autoimmune rheumatologic diseases ...................................................................................................... 19 Bone marrow or stem cell transplantation ............................................................................................... 37 Cytokines/chemokines ............................................................................................................................ 42 Diabetes and other autoimmune endocrine diseases .............................................................................. 47 General Autoimmunity…………………………………………………………………………………………….58 Genetics .................................................................................................................................................. 70 Immune monitoring .................................................................................................................................. 74 Immunity & infection ................................................................................................................................ 82 Immunodeficiency:
    [Show full text]
  • Granulocyte Colony-Stimulating Factor (G-CSF)
    British Journal of Cancer (1999) 80(1/2), 229–235 © 1999 Cancer Research Campaign Article no. bjoc.1998.0344 Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response E Reyes1, I García-Castro2, F Esquivel1, J Hornedo2, H Cortes-Funes2, J Solovera3 and M Alvarez-Mon1 1Medicine/Immune System Diseases Oncology Service, Department of Medicine ‘Principe de Asturias’ University Hospital, Alcalá University, Carretera Madrid- Barcelona, Km 33.600, 28871 Alcalá de Henares, Madrid, Spain; 2Medical Oncology Department, ‘12 de Octubre’ University Hospital, Madrid, Spain; 3Amgen, S.A. Barcelona, Spain Summary Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production.
    [Show full text]
  • Cytokines As Cellular Pathophysiology of Many Diseases
    Review Mediators of Inflammation, 5, 417-423 (1996) CYTOKINES and their receptors are involved in the Cytokines as cellular pathophysiology of many diseases. Here we pre- sent a detailed review on cytokines, receptors and communicators signalling routes, and show that one important lesson from cytokine biology is the complex and diverse regulation of cytokine activity. The activ- cA ity of cytokines is controlled at the level of trans- R. Debets and H. F. J. Savelkoul cription, translation, storage, processing, post- translational modification, trapping, binding by soluble proteins, and receptor number and/or Department of Immunology, Erasmus University, function. Translation of this diverse regulation in P.O. Box 1738, 3000 DR Rotterdam, The Netherlands strategies aimed at the control of cytokine activity will result in the development of more specific and selective drugs to treat diseases. CACorresponding Author Key words: Control of activity, Cytokine, Interference in cytokine activity, Receptor, Signalling routes Introduction lation and act locally to restore homeostasis. Cytokines bind with high affinity to specific For over two decades, it has been recognized receptors on the surface of target cells. When that immune-competent cells produce peptide cytokine receptors are expressed on the cyto- mediators, now termed cytokines. Cytokines act kine-producing cell, autocrine cellular activation as chemical communicators between cells, but may be the result. If the receptor is expressed mostly not as effector molecules in their own on a neighbouring cell, binding may result in right. The biological function of many cytokines paracrine cytokine activation. These features is mediated through their ability to regulate could explain the sometimes high local concen- gene expression in target cells.
    [Show full text]
  • Following High-Dose Chemotherapy and Autologous Bone Marrow Transplantation
    Bone Marrow Transplantation, (1997) 19, 315–322 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 A phase I trial of recombinant human interleukin-1b (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation M Elkordy, M Crump, JJ Vredenburgh, WP Petros, A Hussein, P Rubin, M Ross, C Gilbert, C Modlin, B Meisenberg, D Coniglio, J Rabinowitz, M Laughlin, J Kurtzberg and WP Peters Duke University, Bone Marrow Transplant Program, Durham, NC, USA Summary: The use of lineage-specific hematopoietic growth factors such as GM-CSF and G-CSF shortens the duration of neu- We studied the effects of escalating doses of recombi- tropenia following high-dose chemotherapy and ABMT.1–3 nant human IL-1b in patients receiving high-dose Recently with molecular cloning much interest has emerged chemotherapy and ABMT for metastatic breast cancer in the use of growth factors, which have multilineage pro- or malignant melanoma. Sixteen patients received IL- liferative effects, to shorten the duration of neutropenia and 1b, 4 to 32 ng/kg/day administered subcutaneously for platelet transfusion-dependence and to decrease the number 7 days beginning 3 h after bone marrow infusion. Three of red blood cell transfusions.4 patients at the highest dose level also received G-CSF IL-1b is a polypeptide which exerts effects on hemato- following completion of IL-1b. All patients completed poiesis through several mechanisms, and produces a broad the 7 days of therapy. The majority of patients experi- spectrum of metabolic, immunologic and inflammatory enced chills and fever following one or more injections, effects.5,6 In addition to having a direct stimulatory effect and seven had severe pain at the injection site.
    [Show full text]
  • The Immunomodulatory Impact of Multipotential Stromal Cells on Monocytes in Healthy People and Patients with Rheumatoid Arthritis
    The immunomodulatory impact of multipotential stromal cells on monocytes in healthy people and patients with rheumatoid arthritis Priyanka Dutta Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds Faculty of Medicine and Health School of Medicine September 2020 Primary Supervisor: Professor Michael McDermott Secondary Supervisor: Dr Elena Jones Secondary Supervisor: Professor Graham Cook The candidate confirms that the work submitted is her own work and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and no quotation from the thesis may be published without proper acknowledgement. The right of Priyanka Dutta to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. i Acknowledgements I would like to express my deep gratitude to my supervisors Professor Michael McDermott, Dr Elena Jones and Professor Graham Cook for providing me with this opportunity. Thank you for all your understanding, guidance and immense support inside and outside of the lab. Thanks for sharing your knowledge and ideas to support this PhD work, most of all thank you for your patience. Also, thanks to Chi Wong, Rekha Parmar, Adam Davidson and Elizabeth Straszynski for their great support in the lab, as well as the staff and patients at Chapel Allerton Hospital for providing patient samples. Thank you to Professor Paul Genever for providing the Y201 and Y202 MSC immortalised cell lines and to Dr Andreia Riberio and Professor Rhodri for their expert advice on optimisation of the whole blood assay.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen Et Al
    US 2013 02374.39A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen et al. (43) Pub. Date: Sep. 12, 2013 (54) SYSTEMIS AND METHODS USING Publication Classification BOMARKERPANEL, DATA (71) Applicants: Craig M. Stolen, New Brighton, MN (51) Int. Cl. (US); Timothy E. Meyer, North Oaks, GOIN33/68 (2006.01) MN (US); Milan Seth, Minneapolis, MN (52) U.S. Cl. (US); Francis G. Spinale, Blythewood, CPC .................................. G0IN33/6893 (2013.01) SC (US); Nicholas David Wold, Arden USPC .............................................. 506/9; 435/7.92 Hills, MN (US) (72) Inventors: Craig M. Stolen, New Brighton, MN (US); Timothy E. Meyer, North Oaks, (57) ABSTRACT MN (US); Milan Seth, Minneapolis, MN (US); Francis G. Spinale, Blythewood, SC (US); Nicholas David Wold, Arden Embodiments of the disclosure are related to systems and Hills, MN (US) methods for utilizing biomarker panel data with respect to (73) Assignees: MEDICAL UNIVERSITY OF medical devices and methods, amongst other things. In an SOUTH CAROLINA, CHARLESTON, embodiment, the disclosure can include a method of predict SC (US); CARDIAC PACEMAKERS, ing the likelihood of response to CRT therapy. The method INC., ST. PAUL, MN (US) can include quantifying levels of one or more biomarkers in a (21) Appl. No.: 13/756,129 biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of (22) Filed: Jan. 31, 2013 biomarkers includes at least two selected from the group Related U.S. Application Data consisting of CRP, SGP-130, SIL-2R, STNFR-II, IFNg, BNP (60) Provisional application No.
    [Show full text]
  • Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications
    Review Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications Pushpalatha Palle 1,2,†, Kelly L. Monaghan 1,2,†, Sarah M. Milne 1,2 and Edwin C.K. Wan 1,2,* 1 Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA; [email protected] (P.P.); [email protected] (K.L.M.); [email protected] (S.M.M.) 2 Center for Basic and Translational Stroke Research and the Center for Neurodegenerative Diseases, Blanchette Rockefeller Neurosciences Institute, West Virginia University School of Medicine, Morgantown, WV 26506, USA * Correspondence: [email protected]; Tel.: +1‐304‐263‐6293; Fax: +1‐304‐293‐7823 † These authors contributed equally to this work. Received: 22 August 2017; Accepted: 11 October 2017; Published: 13 October 2017 Abstract: Multiple sclerosis (MS) is one of the most common neurological disorders in young adults. The etiology of MS is not known but it is widely accepted that it is autoimmune in nature. Disease onset is believed to be initiated by the activation of CD4+ T cells that target autoantigens of the central nervous system (CNS) and their infiltration into the CNS, followed by the expansion of local and infiltrated peripheral effector myeloid cells that create an inflammatory milieu within the CNS, which ultimately lead to tissue damage and demyelination. Clinical studies have shown that progression of MS correlates with the abnormal expression of certain cytokines. The use of experimental autoimmune encephalomyelitis (EAE) model further delineates the role of these cytokines in neuroinflammation and the therapeutic potential of manipulating their biological activity in vivo.
    [Show full text]
  • An Emerging Role for the Anti-Inflammatory Cytokine
    Tsai et al. Journal of Biomedical Science 2013, 20:40 http://www.jbiomedsci.com/content/20/1/40 REVIEW Open Access An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection Tsung-Ting Tsai1,2, Yi-Jui Chuang2,3, Yee-Shin Lin1,3,4, Shu-Wen Wan3,4, Chia-Ling Chen3,4 and Chiou-Feng Lin1,2,3,4* Abstract Infection with dengue virus (DENV) causes both mild dengue fever and severe dengue diseases, such as dengue hemorrhagic fever and dengue shock syndrome. The pathogenic mechanisms for DENV are complicated, involving viral cytotoxicity, immunopathogenesis, autoimmunity, and underlying host diseases. Viral load correlates with disease severity, while the antibody-dependent enhancement of infection largely determines the secondary effects of DENV infection. Epidemiological and experimental studies have revealed an association between the plasma levels of interleukin (IL)-10, which is the master anti-inflammatory cytokine, and disease severity in patients with DENV infection. Based on current knowledge of IL-10-mediated immune regulation during infection, researchers speculate an emerging role for IL-10 in clinical disease prognosis and dengue pathogenesis. However, the regulation of dengue pathogenesis has not been fully elucidated. This review article discusses the regulation and implications of IL-10 in DENV infection. For future strategies against DENV infection, manipulating IL-10 may be an effective antiviral treatment in addition to the development of a safe dengue vaccine. Keywords: DENV, Antibody-dependent
    [Show full text]
  • Effects of Biological Therapies on Molecular Features of Rheumatoid
    International Journal of Molecular Sciences Review Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis , Chary Lopez-Pedrera * y , Nuria Barbarroja y, Alejandra M. Patiño-Trives, Maria Luque-Tévar, Eduardo Collantes-Estevez , Alejandro Escudero-Contreras z and Carlos Pérez-Sánchez z Rheumatology Service, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, E-14004 Córdoba, Spain; [email protected] (N.B.); [email protected] (A.M.P.-T.); [email protected] (M.L.-T.); [email protected] (E.C.-E.); [email protected] (A.E.-C.); [email protected] (C.P.-S.) * Correspondence: [email protected] or [email protected]; Tel.: +34-957-213-795 These authors shared first authorship. y These authors shared last authorship. z Received: 31 October 2020; Accepted: 27 November 2020; Published: 28 November 2020 Abstract: Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients.
    [Show full text]
  • WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 1/36 (2006.01) A61K 38/19 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/28 (2006.01) A61M 1/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, PCT/IB2013/001583 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 3 1 May 2013 (3 1.05.2013) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, PCT/EP20 12/002340 1 June 2012 (01 .06.2012) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 12196527.
    [Show full text]
  • Subunit Α Receptor Shedding of the Cell Surface GM-CSF Monocytes
    Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human This information is current as Monocytes: Evidence for Ectodomain of September 25, 2021. Shedding of the Cell Surface GM-CSF Receptor α Subunit Jay M. Prevost, Jennifer L. Pelley, Weibin Zhu, Gianni E. D'Egidio, Paul P. Beaudry, Carin Pihl, Graham G. Neely, Downloaded from Emmanuel Claret, John Wijdenes and Christopher B. Brown J Immunol 2002; 169:5679-5688; ; doi: 10.4049/jimmunol.169.10.5679 http://www.jimmunol.org/content/169/10/5679 http://www.jimmunol.org/ References This article cites 39 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/169/10/5679.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor ␣ Subunit1 Jay M.
    [Show full text]